Results 51 to 60 of about 11,014 (267)

Risk factors for transmission of Ebola or Marburg virus disease: a systematic review and meta-analysis [PDF]

open access: yes, 2015
Background The Ebola virus disease outbreak that started in Western Africa in 2013 was unprecedented because it spread within densely populated urban environments and affected many thousands of people.
Baron   +26 more
core   +1 more source

Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses. [PDF]

open access: yes, 2017
Until recently, immune responses in filovirus survivors remained poorly understood. Early studies revealed IgM and IgG responses to infection with various filoviruses, but recent outbreaks have greatly expanded our understanding of filovirus immune ...
Cose, S   +11 more
core   +4 more sources

AAV Vectored Immunoprophylaxis for Filovirus Infections [PDF]

open access: yesTropical Medicine and Infectious Disease, 2020
Filoviruses are among the deadliest infectious agents known to man, causing severe hemorrhagic fever, with up to 90% fatality rates. The 2014 Ebola outbreak in West Africa resulted in over 28,000 infections, demonstrating the large-scale human health and economic impact generated by filoviruses.
Amira D. Rghei   +8 more
openaire   +3 more sources

Cryoelectron microscopic structure of the nucleoprotein–RNA complex of the European filovirus, Lloviu virus

open access: yesPNAS Nexus, 2023
Lloviu virus (LLOV) is a novel filovirus detected in Schreiber's bats in Europe. The isolation of the infectious LLOV from bats has raised public health concerns. However, the virological and molecular characteristics of LLOV remain largely unknown.
Shan Hu   +7 more
semanticscholar   +1 more source

Cytokine Effects on the Entry of Filovirus Envelope Pseudotyped Virus-Like Particles into Primary Human Macrophages

open access: yesViruses, 2019
Macrophages are one of the first and also a major site of filovirus replication and, in addition, are a source of multiple cytokines, presumed to play a critical role in the pathogenesis of the viral infection. Some of these cytokines are known to induce
Tzanko S. Stantchev   +5 more
doaj   +1 more source

Preexisting immunity does not prevent efficacy of VSV-based filovirus vaccines in nonhuman primates.

open access: yesJournal of Infectious Diseases, 2023
Ebola virus (EBOV) and Marburg virus (MARV) made headlines in the past decade causing outbreaks of human disease in previously nonendemic yet overlapping areas. While EBOV outbreaks can be mitigated with licensed vaccines and treatments, there is not yet
A. Marzi   +5 more
semanticscholar   +1 more source

Detection of filovirus-reactive antibodies in Australian bat species

open access: hybridJournal of General Virology, 2022
Jennifer Barr   +13 more
openalex   +2 more sources

Viewpoint: filovirus haemorrhagic fever outbreaks: much ado about nothing? [PDF]

open access: yes, 2000
The recent outbreak of Marburg haemorrhagic fever in the Democratic Republic of Congo has put the filovirus threat back on the international health agenda.
Boelaert, M   +7 more
core   +3 more sources

Filovirus assembly and budding

open access: yesVirology, 2006
Filoviruses belong to the order of negative-stranded non-segmented RNA viruses and are classified into two genera, Ebola and Marburg viruses. They have a characteristic filamentous shape, which is largely determined by the matrix protein VP40. Although VP40 is the main driving force for assembly and budding from the host cell, the production of ...
Hartlieb, Bettina, Weissenhorn, Winfried
openaire   +2 more sources

Developing Vaccines to Improve Preparedness for Filovirus Outbreaks: The Perspective of the USA Biomedical Advanced Research and Development Authority (BARDA)

open access: yesVaccines, 2023
Outbreaks of viral hemorrhagic fever caused by filoviruses have become more prevalent in recent years, with outbreaks of Ebola virus (EBOV), Sudan virus (SUDV), and Marburg virus (MARV) all occurring in 2022 and 2023.
Lindsay A. Parish   +3 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy